AstraZeneca PLC

AstraZeneca develops and sells prescription drugs for cancer (Tagrisso, Lynparza, Imfinzi, Enhertu), heart disease and diabetes (Farxiga, Brilinta, Crestor), respiratory conditions (Symbicort, Fasenra, Breztri), and rare diseases (Soliris, Ultomiris, Strensiq) [Company Overview]. The company sells through distributors and local offices across the UK, Americas, Europe, Asia, Africa, and Australasia, serving primary care doctors and specialists [Company Overview]. Strategic partnerships with Tempus, Pathos, and CSPC Pharmaceutical aim to advance AI-driven oncology research and novel oral drug candidates [Company Overview].

AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, UK, with 96,100 employees focused on discovering, developing, and commercializing prescription medicines across oncology, cardiovascular, respiratory, immunology, and rare diseases [Company Overview]. The company generated $58.7B in revenue with strong margins (81.9% gross, 24.0% operating) and a solid financial health score of 8.9/10 [Yahoo Finance]. A recent 1:2 stock split on February 2, 2026, doubled the share count, making per-share historical comparisons require adjustment [EODHD].

AstraZeneca is financially healthy with strong revenue growth, excellent margins, and manageable debt [Yahoo Finance].